Neurex
Executive Summary
Menlo Park, Calif.-based CNS drug R&D firms acquires privately held Creagen for 1.95 mil. shares of Neurex stock. Creagen's thrombolytic agent pro-urokinase is in Phase II trials, and the company also has discovered a "unique approach to protein engineering," Neurex says